Published in Antimicrob Agents Chemother on January 01, 2002
In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis (2003) 1.16
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother (2003) 0.95
Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms. Antimicrob Agents Chemother (2003) 0.86
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. Antimicrob Agents Chemother (2004) 0.83
Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother (2004) 0.81
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother (2000) 3.08
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 2.88
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother (1999) 1.19
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci (2000) 5.53
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 3.65
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology (2000) 2.67
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol (1996) 2.60
Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 2.59
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther (1989) 2.29
Sub-ice foraging behavior of emperor penguins. J Exp Biol (2000) 2.26
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood (1990) 2.08
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood (1992) 2.07
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Lower motor neuron degeneration associated with type C RNA virus infection in mice: neuropathological features. J Neuropathol Exp Neurol (1974) 2.00
The Veterans Affairs Continuous Improvement in Cardiac Surgery Study. Ann Thorac Surg (1994) 1.96
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother (1988) 1.82
Continuous assessment and improvement in quality of care. A model from the Department of Veterans Affairs Cardiac Surgery. Ann Surg (1994) 1.80
Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology (1998) 1.79
Infection with human T-cell leukemia virus type I in patients with leukemia. N Engl J Med (1988) 1.78
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol (1979) 1.74
Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat Biotechnol (2001) 1.70
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother (1981) 1.65
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother (1991) 1.63
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother (1981) 1.60
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. J Antimicrob Chemother (1999) 1.58
Borderline increases in albumin excretion rate and the relation to glycemic control in subjects with type I diabetes. Clin Chem (1991) 1.58
Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother (1989) 1.57
Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology (1981) 1.55
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother (1999) 1.50
Human immunodeficiency virus seroprevalence in primary care practices in the United States. West J Med (1993) 1.50
Ultrastructural studies of multiple sclerosis. Lab Invest (1969) 1.49
Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine. Free Radic Biol Med (1992) 1.49
Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother (1982) 1.49
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J Biol Chem (1994) 1.46
Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother (1982) 1.42
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother (1983) 1.42
Salvage angioplasty: an alternative to high risk surgery for unstable angina? Cathet Cardiovasc Diagn (1992) 1.40
Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother (2002) 1.40
The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents (1994) 1.38
Neuronally restricted RNA splicing regulates the expression of a novel GABAA receptor subunit conferring atypical functional properties [corrected; erratum to be published]. J Neurosci (1997) 1.38
Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother (2001) 1.38
Problems with Iso-Sensitest agar. J Antimicrob Chemother (1990) 1.38
The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother (1993) 1.38
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother (1998) 1.37
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother (1993) 1.37
Effects of storage time and temperature on measurement of small concentrations of albumin in urine. Clin Chem (1990) 1.35
Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother (1998) 1.33
Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol (1976) 1.31
Comparison of sensititre dried microtitration trays with a standard agar method for determination of minimum inhibitory concentrations of antimicrobial agents. Antimicrob Agents Chemother (1980) 1.30
Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci (1999) 1.30
Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax (1988) 1.29
Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2005) 1.28
The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 1.27
In vitro activities of two glycylcyclines. Antimicrob Agents Chemother (1994) 1.27
6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors. J Antimicrob Chemother (1981) 1.27
Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol (2001) 1.26
Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother (1995) 1.25
Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med (1993) 1.24
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother (1995) 1.22
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother (1998) 1.22
Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother (1988) 1.21
In vitro activity of CGP 31608, a new penem. Antimicrob Agents Chemother (1987) 1.21
Impact of mammary grafts on coronary bypass operative mortality and morbidity. Department of Veterans Affairs Cardiac Surgeons. Ann Thorac Surg (1994) 1.19
Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA (1991) 1.19
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother (1999) 1.19